SEC Filing Summary
Filing identity and period: The supplied filing is a Form 10-Q for DanDrit Biotech USA, Inc. and subsidiary, not Lunai Bioworks Inc. It covers the three and six months ended December 31, 2015, with comparative periods ended December 31, 2014. The filing was signed February 12, 2016. The company changed its fiscal year-end from December 31 to June 30 in June 2015.
Business Context and Reporting Period
DanDrit is a Delaware holding company whose Danish subsidiary develops, manufactures, and conducts clinical trials for dendritic-cell cancer vaccines, principally MelCancerVac (MCV) for colorectal cancer. MCV sales were limited to compassionate-use activity in Singapore, and the product was not approved for general sale in other locations.
The company was conducting Phase IIb/III and planned Phase III clinical activities while pursuing additional financing. The financial statements are unaudited, condensed interim statements prepared under U.S. GAAP.
Financial Performance and Position
| Metric | Three Months Ended Dec. 31, 2015 | Three Months Ended Dec. 31, 2014 | Six Months Ended Dec. 31, 2015 | Six Months Ended Dec. 31, 2014 |
|---|---|---|---|---|
| Revenue | $42,525 | $0 | $42,525 | $0 |
| Gross profit (loss) | $37,281 | $(70,161) | $37,281 | $(213,656) |
| Operating expenses | $632,221 | $865,117 | $973,616 | $1,235,362 |
| Operating loss | $(594,940) | $(935,278) | $(936,335) | $(1,449,018) |
| Net loss | $(421,776) | $(953,131) | $(772,078) | $(1,488,374) |
| Basic and diluted loss per share | $(0.04) | $(0.11) | $(0.08) | $(0.175) |
Margins: The second-quarter gross margin was approximately 87.7%, compared with a negative gross margin in the prior-year quarter. The operating margin was approximately negative 1,399%, and the net margin was approximately negative 992%, reflecting the company’s very limited revenue base and continuing development costs. Six-month gross margin was also approximately 87.7%; operating and net margins remained substantially negative.
- Cash and liquidity: Cash was $531,260 at December 31, 2015, compared with cash and cash held in escrow of $1,474,134 at June 30, 2015. Working capital was $328,129 versus $910,522 at June 30, 2015.
- Cash flow: Six-month operating cash use was $1,082,871, compared with $1,392,199 in the prior-year period. Investing cash flow was a $1,052,989 source, primarily from release of cash held in escrow. Financing cash flow was zero, compared with $5,811,043 of financing cash inflow in the prior-year period.
- Assets and liabilities: Total assets were $1,335,686, including $140,415 of net definite-life intangible assets. Current liabilities were $893,914, including $101,382 of related-party notes payable, $526,346 of accounts payable, $96,897 of related-party accounts payable, and $169,289 of accrued expenses.
- Equity: Stockholders’ equity declined to $441,772 from $1,077,140 at June 30, 2015. Accumulated deficit was $25,337,533.
- Shares: 9,533,290 common shares were reported outstanding at December 31, 2015 and as of February 12, 2016, including 185,053 shares reserved for non-consenting shareholders and deemed issued for accounting purposes.
Material Changes Versus the Prior Comparable Period
- Revenue increased from zero to $42,525 in both the quarter and six-month period, primarily from a final payment on Project Naimet and a smaller lysate sale connected with the Singapore compassionate-use program.
- Gross results improved from a $70,161 loss to $37,281 profit for the quarter and from a $213,656 loss to $37,281 profit for the six months, largely because of the Project Naimet payment.
- Quarterly operating expenses decreased 27% to $632,221; six-month expenses decreased 21% to $973,616. The main reductions were in general and administrative, consulting, legal, audit, and equity-financing-related costs.
- Research and development expense increased from zero to $277,648 for the quarter and $379,407 for six months, reflecting Phase IIb/III clinical trial activity.
- Net loss improved 56% for the quarter and 48% for the six months, but the company remained dependent on external financing.
- Currency transaction losses increased to $166,348 for the quarter and $198,576 for the six months, compared with $40,927 and $40,801, respectively, in the prior-year periods.
- Cash declined materially because of operating cash burn, research and development spending, and the change in cash held in escrow.
Guidance, Outlook, Risks, and Unusual Items
Management provided no quantitative revenue or earnings guidance. Its stated plan was to continue raising capital and generate revenue from MCV compassionate-use sales while advancing clinical development.
- Management stated that the company had significant historical losses and insufficient working capital for projected losses and planned Phase III testing, but considered the going-concern issue alleviated by two stated capital commitments of $1,000,000 each, one from a shareholder and one from an individual. Both commitments were dated July 10, 2015 and expire July 10, 2016.
- Management expected cash, potential loans, shareholder commitments, and other sources to fund anticipated needs for the next twelve months, but warned that unexpected expenditures could materially strain liquidity.
- The company expected to raise additional capital through common-stock sales and future compassionate-use product sales. Financing may not be available on acceptable terms or at all.
- MCV remained subject to significant regulatory, clinical, manufacturing, product-liability, and commercialization risks. FDA approval was not assured, and current sales were restricted to compassionate-use activity.
- The company recorded $12,048 of losses on abandoned assets within depreciation and amortization for the six-month period.
- Related-party activity included $44,365 of medical consultancy payments, $29,765 of legal services from a firm partially owned by the chairman, and $96,897 payable to that law firm at December 31, 2015.
- The filing reported no material pending legal proceedings, no material off-balance-sheet arrangements, and no defaults upon senior securities.
- All deferred tax assets were subject to a valuation allowance. Reported tax loss carryforwards included approximately $9.7 million for Danish tax purposes and $808,668 for U.S. federal tax purposes, subject to applicable limitations.
Facts Investors Should Verify
- Confirm the issuer identity: the source filing names DanDrit Biotech USA, Inc., while the request metadata names Lunai Bioworks Inc.
- Verify whether the two $1 million capital commitments were funded, remain enforceable, and are sufficient relative to the company’s operating cash burn and clinical-trial requirements.
- Assess the company’s ability to obtain FDA or other regulatory approval for MCV and to convert compassionate-use activity into recurring commercial revenue.
- Review clinical-trial status, remaining obligations, and expected costs for the Phase IIb/III and Phase III programs.
- Reconcile the decline in cash and working capital with expected near-term liabilities, including the $101,382 of related-party notes payable and other accrued obligations.
- Evaluate currency exposure, given the Danish operating base and the significant currency transaction losses recorded in 2015.
- Review related-party transactions, consulting arrangements, and the treatment of the 185,053 shares reserved for non-consenting shareholders.